Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines

Sonali Kochhar a,b, Denny Kim c, Jean-Louis Exclerd d, Richard C. Condit e, James S. Robertson f, Stephen Drew g, Mike Whelan h, David Wood f, Patricia E. Fast i, Marc Gurwith k, Bettina Klug l, Najwa Khuri-Bulos m, Emily R. Smith k, Robert T Chen k, For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) 1

a Global Healthcare Consulting, New Delhi, India
b University of Washington, Seattle, WA, USA
c Janssen Pharmaceuticals, Titusville, NJ, USA
d International Vaccine Institute, Seoul, Republic of Korea
e Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA
f Independent Adviser, UK
g Independent Adviser, USA
h Project Leader, CEPI, UK
i International AIDS Vaccine Initiative, New York, NY, USA
j Stanford School of Medicine, Palo Alto, CA, USA
k Brighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA
l Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany
m University of Jordan, Amman, Jordan

Abstract

Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The Brighton Collaboration (www.brightoncollaboration.org) was launched in 2000 to improve the science of vaccine safety [1]. The Brighton Collaboration formed the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008 to improve the ability of key stakeholders to anticipate potential safety issues and meaningfully assess or interpret safety data, thereby facilitating greater public acceptance when viral vector vaccines are licensed [2]. One of the tools developed by the V3SWG is a standardized template describing the key considerations for benefit-risk assessment of viral vector vaccines. Completed by the vaccine developers/sponsors, it will then be peer-reviewed by the V3SWG and published. The information in the template may facilitate communication of otherwise complex and highly technical data among key stakeholders and increase the transparency, comparability, and comprehension of essential information. The template has been used for the standardized risk-assessment of several new viral vector vaccines [3–5], including some targeting Ebola. The WHO Global Advisory Committee on Vaccine Safety (GACVS) endorsed the use of the template for other new candidate Ebola vaccines “as it is a structured approach to vaccine safety” [6].

In 2020, the development of vaccines for COVID-19 is occurring with unprecedented speed [7]. The pace and volume of vaccine development make a deliberate and systematic approach to safety that is accessible and understandable to a diversity of stakeholders of the utmost importance. Several protein vaccine candidates (e.g., recombinant protein or synthetic peptide vaccines) are among the COVID-19 vaccines in development. The Brighton Collaboration V3SWG has therefore developed a specific template for protein vaccines that the Coalition for Epidemic Preparedness Innovations (CEPI) and other key stakeholders could use to evaluate and communicate the benefit-risk assessment of using this platform. See Supplementary Material for definitions and additional guidance for completing this template.

Protein vaccines generally comprise the viral surface antigen responsible for the stimulation of neutralizing antibodies (spike protein in the case of COVID-19) [8]. They are typically recombinant-derived and highly purified. Peptides are also included in this category of vaccines and most of these are likely to be synthetic in nature. Examples of licensed protein vaccines include an influenza vaccine comprising highly purified recombinant hemagglutinin [9], and a herpes zoster vaccine with highly purified varicella zoster surface glycoprotein E antigen [10]. Many other protein vaccines have undergone clinical testing for example HIV gp120 and gp140 vaccines, but are not yet licensed. Recombinant proteins have often been used in vector or DNA prime, and protein boost regimens, in particular for HIV vaccines [11]. Some recombinant viral antigens spontaneously assemble into virus-like particles (VLPs). These may be single or multi protein structures that are stable and more immunogenic compared to purified protein antigens. Examples of licensed vaccines containing recombinant VLPs include hepatitis B and human papillomavirus vaccines [12]. It should be highlighted that, in contrast to inactivated, live attenuated, and viral vectored vaccines, the manufacture of protein vaccines does not involve the cultivation of any live viruses and they do not contain any viral genomes, their production and quality control is simpler, they are generally considered safer in cases where viruses can establish a persistent infection or are oncogenic, and they are feasible to manufacture even if the virus cannot be cultivated. Commercialized recombinant protein vaccines have been shown to be safe and efficacious and their manufacture can be scaled-up with relative ease [13–15]. However, due to the limited immunogenicity of some protein-based vaccines in humans, their development has also focused on methods to enhance the immune response, for example through the use of adjuvants, optimizing the route or method of administration, and the use of a heterologous prime-boost strategies.

In particular, protein vaccines are likely to require a potent adjuvant that will direct the immune response to a predominantly Th1-type response. Adjuvants are not usually licensed per se and it is the adjuvanted vaccine that is granted marketing authorization. There are only a few different types of adjuvant used in commercial vaccines although many are under investigation and the availability of particular adjuvants may be limited. Whilst enhancing the immune response, adjuvants impart additional safety considerations to a vaccine that have to be carefully assessed [16].

The V3SWG intends that this template focuses on key questions related to the essential safety and benefit-risk issues relevant for the intrinsic properties of the vaccine components. Although we recognize that other aspects of manufacturing, quality, and implementation can play an important role in the safety of a vaccine and vaccination, we have chosen to keep some of those issues out of scope in order to summarize the most useful information for stakeholders.

The latest version of the template can be accessed on https://brightoncollaboration.us/v3swg/. Vaccine developers are encouraged to complete the relevant templates for their vaccine candidate platform or vaccine candidate and collaborate with the V3SWG. The draft templates would be shared for review by the V3SWG and submitted for publication. Similarly, updates to the templates by the vaccine developers should be submitted to the Brighton Collaboration website for V3SWG review.

2. Specific instructions for completing the V3SWG template:

- Please read these instructions before you complete the ten sections. Send questions to: brightoncollaborationv3swg@gmail.com
- The first section entitled “Authorship” should include your name and the latest date completing the form. If you are working with someone else to complete this form, their name should be provided as well. If you are updating the form, please provide the updated date. These co-authors will be included in the final published template in Vaccine once reviewed and approved by the V3SWG and in subsequent Wiki updates on the V3SWG website.
- Sections 2–8 collect information regarding the basic vaccine information (Section 2), target pathogen and population (Section 3), characteristics of antigen (Section 4), adjuvant (Section 5), delivery and administration (Section 6), toxicity and nonclinical (Section 7), and human efficacy and other important information (Section 8). Depending on the vaccine, some sections may be redundant or not applicable. In cases of redundancies, an answer may simply refer to the answer in a previous section.
- Answer questions by responding in the column entitled ‘Information.’ If you have any comments or concerns regarding the question or your answer to the question, note these in the ‘Comments/Concerns’ column. Finally, please provide refer-
| 1. Authorship | 2. Basic Vaccine Information | 3. Target Pathogen and Population | 4. Characteristics of Antigen | 5. Adjuvant | 6. Delivery and Administration | 7. Toxicology and Nonclinical | 8. Human Efficacy and Other Important Information | 9. Adverse Event (AE) Assessment of the Vaccine Platform (*see Instructions): | 10. Overall Risk Assessment |
|---------------|-----------------------------|---------------------------------|-----------------------------|-------------|-------------------------------|--------------------------|---------------------------------|--------------------------------|-------------------------------|
| 1.1. Author(s) | 2.1 Vaccine name | 3.1 What is the target pathogen? | 4.1 Is the vaccine likely to induce immunity to all strains/genotypes of the target pathogen? Was there evidence generated? | 5.1 If applicable, describe the type of adjuvant, if it has been tested in humans, whether novel or commercialized, and if applicable, what other vaccines (preventive and therapeutic) are formulated with this adjuvant | 6.1 How might the vaccine formulation (antigen and adjuvant already formulated in the same vial or combined prior to administration) impact the safety profile of the vaccine? | 7.1 What is known about biodistribution of the antigen in its final formulation and mode of administration in animal models? | 8.1 What is the evidence that the vaccine would generate a protective immune response in humans (e.g., natural history, passive immunization, animal challenge studies)? | 9.1 Approximately how many humans have received this vaccine to date? If variants of the vaccine platform, please list separately | 10.1 Please summarize key safety issues of concern identified to date, if any: |
| 1.2. Date completed/updated | 2.2 Protein type (e.g., molecular clamp, virus-like particle, peptide) and any special characteristics | 3.2 What are the disease manifestations caused by the target pathogen in humans, for the following categories: | 4.2 What is known about the immune response to the vaccine in animals and/or humans (binding, functional, and neutralizing antibody, B-cell, T-cell memory, etc.)? | 5.2 What is the rationale for using the adjuvant? | 6.2 If the vaccine is part of a heterologous prime-boost regimen, describe the regimen that this vaccine is a part of and the possible impact on safety | 7.2 How long does the vaccine antigen persist in vivo (may specify in tissue/serum; proximal/distal to site of administration)? | 8.2 Describe other key information that may impact benefit-risk | 9.2 Method(s) used for safety monitoring: |
| 2.3 Type of heterologous expression system used for antigen production (e.g., bacteria, yeast, plants, mammalian or insect cells, chemical synthesis) | 2.4 Adjuvant (if applicable) | 3.3 Is there homology in the sequence of the vaccine antigen and human proteins? | 4.3 What is the mechanism of action of the adjuvant (if known)? | 5.3 How is the adjuvant formulated with the antigen? | 6.3 Describe how components of the vaccine formulation that facilitate stability and delivery into cells (Section 2.5) may impact the safety profile of the vaccine | 7.3 What is the possible risk of autoimmunity or a harmful immune response? | 8.3 Do animal models for toxicity exist? Summarize results | 9.3 Other active surveillance |
| 2.5 Final vaccine formulation components that may impact delivery into cells, stability, and safety (e.g., preservatives (e.g., thimerosal, phenol, | 3.4 How might the adjuvant impact the safety profile of the vaccine? | 4.4 Describe how the mode of vaccine delivery may impact safety (e.g., intramuscular by needle injection, microneedles, intranasal, oral) | 5.4 Do animal models for immunogenicity and/or efficacy exist? Summarize results | 6.4 What is the potential for causing serious unwanted effects and toxicities in: |
| 4.5 How is the adjuvant formulated with the antigen? | 3.5 Do animal models for toxicity exist? Summarize results | 4.5 How might the adjuvant impact the safety profile of the vaccine? | 5.5 How might the adjuvant impact the safety profile of the vaccine? | 6.5 Do animal models for immunogenicity and/or efficacy exist? Summarize results | 7.5 Do animal models for toxicity exist? Summarize results | 8.5 How is the adjuvant formulated with the antigen? | 9.5 Other active surveillance | 10.5 How should they be addressed going forward |
| 1. Authorship | 2. Basic Vaccine Information | 3. Target Pathogen and Population | 4. Characteristics of Antigen | 5. Adjuvant | 6. Delivery and Administration | 7. Toxicology and Nonclinical | 8. Human Efficacy and Other Important Information | 9. Adverse Event (AE) Assessment of the Vaccine Platform (*see Instructions): | 10. Overall Risk Assessment |
|----------------|-------------------------------|---------------------------------|-----------------------------|-----------|-------------------------------|--------------------------------|---------------------------------|--------------------------------|----------------------------------|
|                | 2.6 Route and method of delivery (e.g., intramuscular injection, microneedles, skin patch, intranasal) | ● During pregnancy and in the fetus | 5.6 Summarize the safety findings (preclinical and clinical) with the adjuvant, formulated with any antigen | 7.6 What is the evidence of disease enhancement (if any) in animal models?** | 9.3 What criteria were used for grading the AEs? | ● human neonates, infants, children? | 2007 US FDA Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials | ● pregnancy and in the fetus in humans? | ● elderly |
| ● In elderly | 7.7 Would the vaccine in its final formulation have any impact on innate immunity? If so, what are the implications for benefit-risk? | 7.8 What is the evidence that the vaccine has generated a beneficial immune response in: | ● Small animal models? | 9.4 List and provide frequency of any related or possibly related serious* AEs observed (*see Instructions) | ● in any other special populations (e.g., institutionalized population, individuals with associated chronic comorbidity)? | | | | |
| ● In any other special populations | 3.3 Briefly, what are the key epidemiologic characteristics of the disease caused by the target pathogen (e.g., incubation period, communicable period, route/s of transmission, case fatality rate, transmissibility characteristics such as basic reproductive ratio (R₀))? | 3.4 What sections of the | | | | | | | |
| | benzethonium chloride, 2-phenoxethanol), complexing with polymers, encapsulation within microparticles, liposomes, depot formulations) | | | | | | | | |

---

(continued on next page)
| 1. Authorship | 2. Basic Vaccine information | 3. Target Pathogen and Population | 4. Characteristics of Antigen | 5. Adjuvant | 6. Delivery and Administration | 7. Toxicology and Nonclinical | 8. Human Efficacy and Other Important Information | 9. Adverse Event (AE) Assessment of the Vaccine Platform (*see Instructions): | 10. Overall Risk Assessment |
|---------------|-----------------------------|----------------------------------|-----------------------------|-------------|-------------------------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------|
|               |                             | population are most affected by the target pathogen (e.g., pediatric, pregnant, lactating women (breast-feeding), adult, elderly)? | primates (NHP)? | frequency of any serious, unexpected statistically significantly increased AE or lab abnormality in vaccinee vs. control groups: | Describe the control group: | S. Kochhar et al. / Vaccine 38 (2020) 5734–5739 |
|               |                             | 3.5 What is known about the immune responses, duration, and potential correlates of protective immunity to the target pathogen or to the disease? |               |                         | 9.6 List and provide frequency of Adverse Events of Special Interest | 9.7. Did a Data Safety Monitoring Board (DSMB) or its equivalent oversee the study? | Did it identify any safety issue of concern? | If so describe |
|               |                             | 3.6 Please describe any other key information about the target pathogen or population that may inform benefit-risk |               |                         | | | | |

*Stability is considered here in the context of any relevant intrinsic characteristic of the vaccine deemed relevant for safety purpose.* There are two different syndromes previously associated with vaccine-enhanced disease. One is antibody-dependent enhancement (ADE) and the other is vaccine-associated enhanced respiratory disease (VAERD) [8].
Acknowledgment

We thank the following colleagues for their helpful advice: (1) David Robinson, John Boslego, Brighton Collaboration members; and (2) other members of the V3SWG during the preparation of this document: George Pavlakis, Emmanuel Vidor, Jonathan Smith, Karin Bok, and Merita Kucuku.

References

[1] Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Henninger U, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002;21(3-4):298–302. https://doi.org/10.1016/S0264-410X(02)00449-8.

[2] Chen RT, Carberry B, Mac I, Berns KL, Chapman L, Condit RC, et al. The Brighton Collaboration Virtual Vector Vaccines Safety Working Group (V3SWG). Vaccine 2015;33(1):73–5. https://doi.org/10.1016/j.vaccine.2014.09.035.

[3] Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 2015;33(1):62–72. https://doi.org/10.1016/j.vaccine.2014.10.004.

[4] Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, et al. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine 2016;34(51):6597–609. https://doi.org/10.1016/j.vaccine.2016.06.071.

[5] Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, et al. iSVAG-ZEBOV-GP (also designated VS20) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. Vaccine X 2019:1:100009. https://doi.org/10.1016/j.vaccine.2019.100009.

[6] World Health Organization. Global Advisory Committee on Vaccine Safety, 4–5 December 2019. Ad26.ZEOB/MAV-BN-filo vaccine. Weekly Epidemiol Rev. 2020;95:28–30.

[7] Than Le T, Andreasakis K, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020;19(5):305–6. https://doi.org/10.1038/d41573-020-00073-5.

[8] Graham BS. Rapid COVID-19 vaccine development. Science 2020;368(6494):945–6. https://doi.org/10.1126/science.abb9293.

[9] Cox MM, Patriarca PA, Treanor J, Puthakoya, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses 2008;2(6):211–9. https://doi.org/10.1111/j.1750-2659.2008.00053.x.

[10] Maltez F, Figdor G. Shingrix: A New Herpes Zoster Vaccine. P T. 2019; 44(7):406-33. PMCID: PMC6590925.

[11] Pitsurrunthum P, Berks-Ngarm S, Bussaratid S, Dhitavat J, 2015;33(1):73–5. https://doi.org/10.1016/j.vaccine.2014.09.035.

[12] Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020;52(4):583–9. https://doi.org/10.1016/j.immuni.2020.03.007.

[13] Wang M, Jiang S, Wang Y. Recent advances in the development of recombinant subunit vaccines in Pichia pastoris. Bioengineered 2016;7(3):155–65. https://doi.org/10.1080/21655979.2016.1191707.

[14] Bill RM. Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?. J Pharm Pharmacol 2015;67(3):319–28. https://doi.org/10.1111/jphp.12353.

[15] Chambers AC, Askaal M, Graves LP, Irons SL, Lewis MH, 2003) in the "Reference" column, but please provide the full citation for the reference at the end of the form. Unpublished data are acceptable, though we do wish for you to include the source and contact information.

- Sections 9 and 10 have column titles that differ from preceding sections intended to provide a summary assessment of adverse effects and toxicity of the vaccine. Please summarize adverse effects and toxicities as requested and rate the risk in the following fashion: none, minimal, low, moderate, high, or unknown. If there is insufficient data for use of the platform in humans to accurately make these assessments, please state so in response to the questions.

- When completing information on adverse effects in Section 9, please provide as many details as possible based on the Brighton Collaboration Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies [17].

- If a literature search was conducted to complete any of the Sections (strongly encouraged), please add the following information in the Reference(s) column: 1) time period covered (e.g., month/year to month/year); 2) Medical Subject Headings (MeSH) terms used; 3) the number of references found; and 4) the actual references with relevant information used. For prior published templates, please search PubMed for "Brighton Collaboration V3SWG".

3. Disclaimer

The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the Working Group. They do not necessarily represent the official positions of any participant’s organization (e.g., government, university, or corporations) and should not be construed to represent any Agency determination or policy.

Funding

We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACCines (SPEAR) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.

Declarations of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

ences in the ‘Reference’ column. More than one reference can be used per question. You can simply write the first author’s last name, first name initials, and year of publication (e.g., Lewis MH, 2003) in the “Reference” column here, but please provide the full citation for the reference at the end of the form. Unpublished data are acceptable, though we do wish for you to include the source and contact information.

- Sections 9 and 10 have column titles that differ from preceding sections intended to provide a summary assessment of adverse effects and toxicity of the vaccine. Please summarize adverse effects and toxicities as requested and rate the risk in the following fashion: none, minimal, low, moderate, high, or unknown. If there is insufficient data for use of the platform in humans to accurately make these assessments, please state so in response to the questions.

- When completing information on adverse effects in Section 9, please provide as many details as possible based on the Brighton Collaboration Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies [17].

- If a literature search was conducted to complete any of the Sections (strongly encouraged), please add the following information in the Reference(s) column: 1) time period covered (e.g., month/year to month/year); 2) Medical Subject Headings (MeSH) terms used; 3) the number of references found; and 4) the actual references with relevant information used. For prior published templates, please search PubMed for “Brighton Collaboration V3SWG”.

3. Disclaimer

The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the Working Group. They do not necessarily represent the official positions of any participant’s organization (e.g., government, university, or corporations) and should not be construed to represent any Agency determination or policy.

Funding

We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACCines (SPEAR) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.

Declarations of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.